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Abstract
METABOLIC REPROGRAMMING STEERS STEM CELL EVOLUTION
Juyoung Park
Chider Chen
Remarkable plasticity of stem cells endows them with the ability to adapt
quickly to ever-changing niches throughout a lifetime by reprogramming their
metabolism and function. Upon sensing environmental challenges and following
intrinsic genetic programs, rapidly proliferating progenitor cells during early
postnatal development rewire their metabolic program to convert into quiescent
somatic stem cells for lifelong tissue homeostasis. The molecular switch controlling
this stem cell fate conversion is still obscure. Here we show that neonatal
mesenchymal stem/progenitor cells (nMSCs) exhibit robust stem cell activity with
higher proliferation and multilineage differentiation potential than adult MSCs
(aMSC). The functional robustness of nMSCs requires peroxisome proliferatoractivated receptor-g coactivator-1α (Pgc-1α)-mediated oxidative phosphorylation
(OxPhos) as the metabolic switch which is turned off in aMSCs. The cell fate
conversion between nMSCs and aMSCs by the Pgc-1α-OxPhos switch is
regulated by octamer-binding transcription factor-4 (Oct-4) which directly binds to
the Pgc-1α promoter and induces the promoter activity. The failure to flick on the
metabolic switch by deleting Pgc-1α in nMSCs impedes normal craniofacial growth
and development. By studying stem cells in perinatal transition, these findings
v

underscore the importance of precise metabolic control of stem cell function to
support the life-stage-specific roles of stem cells during craniofacial development
and homeostasis. Based on the newly identified mechanism, this study will
improve our understanding of stem cell evolution processes and will define a novel
metabolic switch to improve stem-cell-based craniofacial tissue regeneration.
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Introduction
Stem-Cell-Based Therapy
Over the past decades, stem-cell-based regenerative therapy has emerged
as an innovative treatment modality for a diverse range of disorders and injuries
by virtue of its proven efficacy, broad applicability, and reduced donor site
complications. Indeed, several orthotopic stem cell therapies, such as limbal stem
cell transplant for corneal regeneration, have given astonishing clinical outcomes
(1,2). Yet, in most of the observed cases, preclinical or clinical trials were not
proven beneficial for reasons related to stem cell types and states, modes of
delivery, and culture conditions (3,4). Previous studies reported that donor aging
and ex vivo expansion significantly affected the clonogenic, proliferative and
differentiative potential of MSCs, substantially limiting their clinical applications (59) (Fig. 1). Strategies to circumvent such drawbacks of using adult stem cells have
been tested such as ectopic expression of pluripotency factor in adult stem cells
to rejuvenate stem cell competence (10,11) or use of in vitro-committed embryonic
stem cells (ESCs) to ensure better function and adaptation upon engraftment (12).
Nonetheless, there is a need for deeper research on molecular signatures
regulating distinct stem cell state and functionality over an organism’s life to attain
greater success rate in regeneration with quality stem cells.

1

Figure 1. Impact of aging on adult stem cells. Aging impairs stem cell functions
and is a significant roadblock to stem-cell-based tissue regeneration. The potential
causes of stem cell aging are: (1) genomic changes by DNA damage and telomere
shortening, (2) dysregulation of proteostasis by altererd chaperone levels and
perturbed autophagy, leading to accumulation of damaged proteins, (3) epigenetic
changes by altered DNA methylation and chromatin structures, (4) mitochondrial
dysfunction by ROS damage and mtDNA mutations, (5) cellular senescence, and
(6) impaired nutrient sensing mechanisms (Figure adapted from Koyuncu, S. et al.
2015, Current Stem Cell Reports (9).).
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Stem Cell Evolution through Lifetime

In an evolutionary perspective, stem cell activity over life span is shaped by
natural selection. Selective pressure during embryogenesis and organismal
growth drives genetic/epigenetic programs in stem cells to assure rapid growth and
development for survival, whereas during adult reproductive phase, stem cells
transmute their programs to maintain and repair tissues to support reproduction
for species propagation. The functionality of stem cells gradually declines during
aging (13,14) (Fig. 2, 3). Evidence for this transition was presented in a lineage
tracing study in which committed osteogenic progenitors not just perinatally
contributed to nascent bone tissues but also to stromal cells in adult marrow,
indicating that early progenitors shift to somatic stem cells for long-term tissue
homeostasis (perinatal shift) (15). More importantly, phenotypes of somatic stem
cells were reversible as heterochronic transplantation and parabiosis studies
suggested that the local and systemic milieu of young mice could ameliorate
dysfunctions in aged stem cells (16,17). This cell plasticity offers intriguing
prospects of reprogramming somatic stem cells by modulating their genomes,
epigenomes, and environment. As such, efforts to uncover molecular mechanisms
involved in stem cell transition should be paralleled by genetic/epigenetic
manipulations to achieve safe and efficient reprogramming (18).

3

Figure 2. Comparison between prenatal and postnatal growth. Prenatal
growth is faster than growth in any other period of life, which is mainly attributed to
the superior activity of embryonic stem cells (Figure adapted and modified from
Lambert, L.J. et al. 2017, Basic Science Methods for Clinical Researchers (19).).

Growth promotion
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Growth suppression
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Growth suppression
Homeostasis decline
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Figure 3. Stem cell transition throughout lifetime. In the early stage of life, stem
cells first evolve to be highly active for tissue formation and growth for the survival
of an organism. But during adult reproductive phase, growth is suppressed, and
stem cells evolve to maintain tissue homeostasis and repair. An organism allocates
its resources either to survival or to reproduction as the two phases are critical for
the species propagation in wildlife. But once the organism is protected from
extrinsic cause of mortality as is the case for domesticated animals, stem cell
function is predicted to be under little evolutionary pressure and eventually
declines during aging (Figure adapted and modified from Goodell, M.A. and Rando,
T.A. 2015, Science (14).).

Epigenetic and Metabolic Remodeling during Stem Cell Transition

Dynamic heterochromatin reorganization occurs during lineage commitment
at the onset of organogenesis. Lineage-committed ESCs accumulate stable
heterochromatic marks on pluripotency (i.e., Oct-4) and non-lineage genes to
constrain pluripotency and preserve lineage fidelity while losing repressive marks
on lineage-specific genes to establish cell identity (20,21). This heterochromatin
reorganization upon organogenesis entails concomitant changes in cellular
metabolic program where ESCs switch from anaerobic to aerobic metabolism with
mitochondrial maturation and respiration that are facilitated by increased oxygen
supply during hematopoiesis and angiogenesis (embryonic shift) (22-24). The
augmented mitochondrial metabolism in aerobic glycolysis supports rapid
proliferation of ESCs by shunting TCA cycle intermediates to be used as
5

biosynthetic precursors while glycolysis quickly generates ATP for energy and
increases the flux into the pentose phosphate pathway for nucleotide synthesis
required for cell division (25-28). This bivalent energetics program further shifts
toward mitochondrial oxidative phosphorylation (OxPhos) which is propitious for
mass ATP production, in the face of an oxygen-rich environment during the
transition from placental to pulmonary circulation at birth (neonatal shift) (29,30).
Accompanying this metabolic shift, cardiomyocyte progenitors exit the cell cycle
and begin maturation to cope with the increased perinatal cardiac workload (30).
Conversely, adult stem cells such as hematopoietic stem cells and MSCs rewire
their metabolic profile from aerobic to anaerobic glycolysis as an adaptation to
hypoxic niche and remain quiescent for lifetime (31-34) (Fig. 4). Still, mechanistic
details of metabolic drivers for the perinatal stem cell transition remain uncovered.

Figure 4. Metabolic reconfiguration during stem cell transition. During
embryonic development, stem cell’s energetics program shifts from anaerobic to
6

aerobic metabolism at the onset of organogenesis. In postnatal life, stem cells
reprogram their metabolic profile back to anaerobic glycolysis to maintain their
stemness and tissue homeostasis (Figure adapted and modified from Baker, C.N.
and Ebert, S.N. 2013, OA Biotechnology (22).).

The Role of Pgc-1α in Life-Stage-Specific Stem Cell Function

Pgc-1α, a versatile coactivator for a variety of transcription factors, has
emerged as a pivotal player which integrates signaling pathways to control cellular
and systemic metabolism (35). When induced by various external signals, Pgc-1α
can stimulate mitochondrial biogenesis and respiratory function by transactivating
numerous mitochondrial genes (36,37). Loss of Pgc-1α has led to substantial
deficiency in oxidative metabolism in multiple tissues, underscoring a vital role of
this cofactor in regulating mitochondrial metabolism (38,39). Notably, Pgc-1α
expression is elevated in neonatal liver and heart accordant with a drastic
expansion of oxidative capacity in these tissues during early postnatal
development (40,41) whereas its expression declines in adult liver (42) and during
muscle aging (43,44). Likewise, our preliminary data have shown a significantly
higher Pgc-1α expression in primary neonatal MSCs (nMSCs) isolated from mouse
mandibles than in adult MSCs (aMSCs), which coincided with higher metabolic
activities of nMSCs than aMSCs as measured by MTT assay (Fig. 22B). The high
metabolic rate of nMSCs was linked to their robust proliferation and differentiation
potential (Fig. 9-12), implying that distinct cellular energetics programs fuel stem
cells at different stages of life to cater for their unique role.
7

Regulation of Stem Cell Metabolism by Oct-4

Metabolic remodeling could represent a mere adaptation of cells to
environments such as substrate availability, oxygen tension, cytokine, or growth
factor signals. Meanwhile, cellular metabolism could be intrinsically regulated by
the cell’s genetic/epigenetic machinery. Oct-4, as a central transcriptional regulator
of pluripotency, maintains pluripotency and self-renewal while suppressing cell fate
specification and differentiation in ESCs (45). Though its expression is gradually
declined by heterochromatinization in differentiating ESCs (46), Oct-4 is still
expressed in adult MSCs and exhibits overlapping functions with ESCs (47). In
fact, genome-wide profiling of Oct-4 targets in ESCs and bone marrow MSCs by
ChIP-DSL revealed common targets, including genes for cellular metabolism and
cell cycle progression (47). In line with this, among the pluripotency factors
screened, our data have shown that Oct-4 expression was significantly higher in
nMSCs than in aMSCs and that this expression pattern was positively correlated
with Pgc-1⍺ expression levels (Fig. 17). Furthermore, we were able to identify
eleven candidate Oct-4 binding motifs on Pgc-1α promoter region, suggesting
possible regulation of Pgc-1α expression by this pluripotency factor (Fig. 36B).

8

Hypothesis

Based on the preliminary data described herein, we hypothesize that Pgc1α is required to promote mitochondrial metabolism and stem cell activity
during perinatal craniofacial development, and that the expression of Pgc1α is regulated by the pluripotency factor Oct-4 (Fig. 5). Defining a role for Pgc1α and related cellular metabolic program in stem cell status and activity as
represented by proliferation and differentiation capacities, and regulatory
mechanisms flicking on this metabolic switch would have great significance in
expanding our understanding of physiological stem cell evolution processes
occurring throughout an organism’s life. Furthermore, investigating the
requirement of metabolic reprogramming in stem cell transition would emphasize
the growing importance of cellular energetics control for proper stem cell function
during craniofacial development and tissue homeostasis. Collectively, to unravel
the novel mechanism by which cellular metabolism controls stem cell function will
greatly advance our knowledge and assuredly enhance the stem-cell-based
regenerative therapy for multiple applications.
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Figure 5. Metabolic reprogramming during stem cell evolution. Distinct
metabolic programs operate in stem cells at different life stages to fulfill their
bioenergetic and/or biosynthetic requirements for appropriate functions. The level
of the pluripotency factor, Oct-4 drives metabolic reprogramming via modulating
Pgc-1α expression.
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Specific Aims
Craniofacial defects such as congenital anomalies (i.e., cleft palate), posttumor ablation or post-traumatic deformities are commonly encountered
pathologies in the cephalic region (48). Correction of dysmorphogenesis or defects
and functional restoration compel extensive surgical intervention involving
autologous bone grafts harvested from donor sites of afflicted individuals. Despite
recent advances in surgical techniques, biomimetic materials and growth factor
treatment, craniofacial reconstruction still confronts major hurdles to surmount,
including donor site morbidity, extended healing time, and graft failure (49). Stem
cell-based therapy holds great promise for regenerative medicine as stem cells are
endowed with self-renewing capability and can constitute multiple specialized cell
types in different tissues, rendering them truly regenerative for tissue engineering
applications (50-52). The success of stem cell-based regeneration depends on
obtaining holoclonogenic stem cells with higher growth potential for sufficient ex
vivo expansion and long-term repopulating capacity for lifetime tissue maintenance
(53). Yet, attempts to use autologous stem cells for multiple diseases and injuries
have faced with limited clinical success due to donor aging or culture senescence
(5-9), posing a significant challenge of applying cell therapy for older patients, the
age population in which need for tissue replacement is higher.

11

Stem cells in different stages of life present distinct identities and functions. In
the early stage of life, stem cells are highly active for tissue formation and
organismal growth, but through adult reproduction stage, growth is suppressed,
and stem cells develop for the maintenance of tissue homeostasis and repair
(13,14). Pluripotency factors, such as Oct-4, intrinsically control the differing stem
cell properties in a way that higher levels of expression correspond to maintenance
of stemness while their gradual loss triggers stem cell differentiation (45). Besides,
metabolic status of stem cells can dictate stem cell fate and behavior. Lineagecommitted progenitor cells at birth utilize both glycolysis and mitochondrial
respiration under higher oxygen concentrations (aerobic glycolysis) to meet both
bioenergetic and biosynthetic requirements of the cell to support rapid proliferation
(25-28). In contrast, tissue-resident adult stem cells rely exclusively on catabolic
glycolysis in their hypoxic niche (anaerobic glycolysis) and remain relatively
quiescent (31-34). Mechanisms by which pluripotency factors, cellular metabolism
and their putative interaction control stem cell status and function have yet to be
fully elucidated in neonatal and adult stem/progenitor cells.

Pgc-1α, a master regulator of mitochondrial biogenesis and function,
reinforces mitochondrial oxidative metabolism when induced by multiple extrinsic
signals (36,37). Our data have shown a significantly higher Pgc-1α expression in
mouse mandible-derived neonatal mesenchymal stem cells (nMSCs) compared to
that of adult MSCs (aMSCs), suggesting potential metabolic differences between
these cells. In line with this, nMSCs had higher metabolic status as measured by
12

NAD(P)H-dependent reductase activity than the adult counterparts. Metabolically
active nMSCs displayed robust proliferation and multilineage differentiation
potential compared to aMSCs. In addition, nMSCs exhibited higher expression of
the pluripotency factor Oct-4 than aMSCs and this expression pattern showed a
positive correlation with the Pgc-1α expression. Moreover, putative Oct-4 binding
sequences were present on the Pgc-1α promoter region, suggesting a possible
regulation of Pgc-1α expression by Oct-4. Together with data described here,
evidence leads to the hypothesis that Pgc-1α is required to promote mitochondrial
metabolism and stem cell activity during perinatal craniofacial development, and
that the expression of Pgc-1α is regulated by the pluripotency factor Oct-4. The
following interrelated Specific Aims will test this hypothesis.

Aim 1: To determine the in vitro requirement of Pgc-1α for mitochondrial
respiration and stem cell function, and the potential regulatory mechanism
for Pgc-1α by Oct-4. Our preliminary studies showed that mitochondrial gene
expression and function, as well as stem cell activities, are attenuated in aMSCs.
This aim will investigate (a) the effects of Pgc-1α depletion on cellular metabolism,
proliferation, and differentiation capacity of MSCs using Pgc-1α knockout (KO)
mice, and (b) the effect of Oct-4 downregulation on Pgc-1α expression and
resultant metabolic changes and MSC function, and the possible regulation of Pgc1α expression by Oct-4 using ChIP-qPCR and luciferase reporter assays.
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Aim 2: To characterize in vivo requirement of Pgc-1α and corresponding
metabolic states for craniofacial development and tissue homeostasis. The
goal of this aim is to use a Pgc-1α KO mouse model to investigate in vivo function
of Pgc-1α in neural-crest-derived MSCs during perinatal craniofacial development
and postnatal tissue maintenance. This aim will investigate the effect of Pgc-1α
deletion on (a) tissue metabolism using immunofluorescence staining, and (b)
craniofacial tissue morphology through histological and micro-CT analyses.

14

Materials and Methods
Animal Models
Wildtype (C57BL/6J) and Pgc1α+/- (B6.129S4(FVB)-Ppargc1atm1Brsp/J) mice were
purchased from the Jackson Laboratory. Mutant lineage was maintained on the
C57BL/6J background via backcrosses. Pgc-1α+/- pairs were crossed to generate
Pgc-1α-/- newborn pups and WT littermates. Genotyping was performed before use
of each animal. Experiments were performed using male and female animals in
approximately equal numbers with no apparent phenotypic difference between
sexes. Two animals (n=2) per group were used to isolate cells for each in vitro
experiment. All phenotypes described in in vivo experiments were representative
of a minimum of 3 littermate pairs (n=3) per group for each experiment. All
experiments were performed in triplicate (n=6 for in vitro or n=9 for in vivo per
group). Animals were randomly allocated to groups and no animals were excluded
from data analysis. Throughout experiments, age-matched littermates were used
as controls. All experiments involving animals were performed in compliance with
institutional guidelines and according to the protocols (#806682) approved by the
Institutional Animal Care and Use Committee (ICAUC) at the University of
Pennsylvania (UPenn).
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Isolation and Preparation of Mandibular MSCs
Primary neonatal (postnatal day 1; P1), postnatal day 7 (P7), and adult (P60)
MSCs were isolated from mouse mandibles and expanded following our previously
established protocol (54). Briefly, mandible harvest was accomplished following
CO2 euthanasia in accordance with American Veterinary Medical Association
(AVMA) guidelines. The attached soft tissues and teeth were removed from the
harvested mandibles. All nucleated cells (ANCs) from mandibles were isolated by
digestion with 2 mg/mL collagenase type I (Worthington Biochem) and 4 mg/mL
dispase II (Roche Diagnostics GmbH) for 1 hour at 37°C. The single-cell
suspensions of ANCs were seeded at 1.5 x 106 on 10 cm culture dishes (Genesee).
after which incubation was carried out with 5% level of CO2 at 37 °C. Non-adherent
cells were removed after 48 hours. Adherent cells were cultured in alpha minimum
essential medium (α-MEM, Invitrogen) for additional 14 days. α-MEM was
supplemented with 20% fetal bovine serum (FBS, Sigma), 2 mM L-glutamine
(Gibco), 55 μM 2-mercaptoethanol (Gibco), 100 U/mL penicillin and 100 μg/mL
streptomycin (Gibco). Passage one and two mandibular MSCs were used for all
the experiments. The morphology of mouse neonatal and adult mandibular MSCs
was shown below (Fig. 6). For the colony-forming units-fibroblast (CFU-F) assay,
single-cell suspensions of ANCs were seeded at different densities on 6 cm culture
dishes (Genesee). After 14 days, cells were stained with 1% toluidine blue solution
in 2% paraformaldehyde (PFA, Sigma-Aldrich). The number of colonies was then
counted under a microscope. A cluster with 50 or more cells were considered as
a colony.
16

Figure 6. Cell morphology of mandible derived MSCs. Microscopic images
showing the size and morphological differences between neonatal (P1) and adult
(P60) mandible derived MSCs isolated from C57BL/6J mice. Typical fibroblast-like
cells start dominating colonies in both MSC groups after the first subculture.
nMSCs are slightly larger in size compared to aMSCs. Scale bar, 25μm.

Micro-Computed Tomography Analysis
Micro-CT scan and analysis were performed following our previous protocols (55).
Briefly, mouse heads and hindlimbs were harvested and fixed for 24 hours in 4%
PFA solution. The fixed head and hindlimb specimens were scanned using a
Scanco μCT35 scanner (Scanco Medical AG) at 45 kVp, 177 μA, and a voxel size
of 6 μm. Reconstruction and data analysis were performed according to the
manufacturer’s instruction. The variations in overall craniofacial morphology and
growth patterns were evaluated with the 3D reconstructed images. For quantitative
analyses, mandibular volume (mm3) and femoral BMD (mg/cm3) were also
measured for each mouse genotype.
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Histological and Histomorphometry Analysis
Hematoxylin and eosin (H&E) staining was performed to assess tissue morphology
and trabecular bone architecture of select craniofacial bones. Briefly, bone
samples were fixed in 4% PFA and decalcified with 10% EDTA (pH 7.4, SigmaAldrich). EDTA solution was changed biweekly for 3 weeks to maintain the
adequate pH level. After decalcification, tissue samples were embedded in paraffin
and sliced into 10 μm-thick sections using a microtome. Paraffin sections were
stained with H&E and analyzed using NIH ImageJ software to measure mandibular
areas.

Whole-Mount Skeletal Staining Preparation
Whole-mount skeletal staining was performed to evaluate the morphology and
skeletal maturation of craniofacial bones. First, fetuses were deskinned and
eviscerated, then fixed in 100% ethanol (EtOH) at room temperature (RT) for 24
hours. Then, the specimens were kept in 100% acetone at RT for another 24 hours.
Fetus samples were incubated in staining solution (1 vol. of 0.3% Alcian blue in
70% EtOH, 1 vol. of 0.1% alizarin red S in 95% EtOH, 1 volume of absolute acetic
acid, and 17 volumes of 70% EtOH) for 3 to 4 days at 37°C on a rocker. Samples
were rinsed with ddH2O and kept in 1% potassium hydroxide (KOH) overnight at
RT with additional incubation until complete tissue clearing. For long term storage,
specimens were transferred into the series of 20%, 50% and 80% glycerol washes.
Fetus samples were photographed and stored in 80% glycerol/1% KOH solution
at RT. All reagents were purchased from the Sigma-Aldrich.
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Immunofluorescence Staining
For cells, mandible derived MSCs (1.0×104/well) were seeded on 2-well chamber
slides (Nunc) and cultured for 60%-70% confluence. Then the cells were fixed with
4% PFA for 10 minutes at RT. For histological sections, mandibular specimens
were deparaffined by xylene and rehydrated by EtOH and ddH2O. Cell or tissue
samples were then permeabilized with PBS containing 0.1% Triton X for 30 min at
RT. Samples were blocked with 10% goat serum for 15 minutes (for cell) or for 1
hour (for tissue) to reduce non-specific binding. Then, the samples were incubated
with primary antibodies (1:200 for cell, 1:100 for tissue) overnight at 4°C, followed
by PBS wash and incubation with appropriate secondary antibodies (1:200)
conjugated with Alexa fluor 488 or 568 for 1 hour at RT. The samples were
mounted with Vectashield mount media containing DAPI (Vector Laboratories).
Images were obtained using fluorescence microscopy (Olympus IX71) and used
to calculate the % positive cells or % positive areas.

MTT Assay
For MTT assay, mandibular MSCs (1×104 cells/well) were seeded onto 96-well
culture plates. After cells were attached, 20 μl MTT reagent (Millipore) was added
into each well and cells were incubated at 37°C for 4 hours in a CO2 incubator.
Then, 150 μl DMSO (Sigma-Aldrich) was added into each well and the culture plate
was placed on a rocker for 10 min at a low speed. The absorbance of Formazan
solution was measured using a microplate reader (BioTek ELx800) at 490 nm.
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RNA Isolation and Real-time qPCR
Total RNA was isolated by using TRIZOL reagent and miRNeasy Mini Kit (Qiagen)
from the cultured cells according to the manufacturer’s instructions. SuperScript III
Reverse Transcriptase kit (Invitrogen) was used to prepare the cDNA. RT-qPCR
assays were performed using SYBR Green Supermix (Bio-Rad) and gene specific
primer pairs. All primers used in this study were synthesized and purified by
Integrated DNA Technologies. The RNA expression was normalized to Gapdh. A
CFX96 Real-Time PCR System (Bio-Rad) was used for RT-qPCR analysis.

RNA Sequencing
After RNA extraction, mRNA was enriched using oligo(dT) beads. For library
preparation, the mRNA was fragmented randomly by adding fragmentation buffer,
then the cDNA is synthesized by using mRNA template and random hexamer
primer, after which a custom second-strand synthesis buffer, dNTPs, RNase H and
DNA polymerase I are added to initiate the second-strand synthesis (Illumina).
After a series of terminal repair, sequencing adaptor ligation and the doublestranded cDNA library were completed through size selection and PCR enrichment.
The qualified libraries were fed into Illumina sequencers after pooling according to
its effective concentration and expected data volume.
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Antibodies and Reagents
The antibody for Alp was purchased from the Santa Cruz Biotechnology. Runx2,
Nestin, β3-tubulin, NeuN, Pgc-1α and Ki-67 antibodies were purchased from the
Cell Signaling Technology, and anti-β-Actin antibody was purchased from the
Sigma-Aldrich. Unconjugated monoclonal antibody for Oct-4 was purchased from
the Millipore. Acan antibody was purchased from the Abcam. Glut-1, Ldha, CS,
and Idh3a antibodies were purchased from the Novus Biologicals. Col-2 antibody
was purchased from the MP Biomedicals. Secondary antibodies for Alexa Fluor
488 and Alexa Fluor 568 were purchased from the Invitrogen. The antibody for
Ppar-γ was purchased from the Santa Cruz Biotechnology, and antibody for Lpl
was purchased from the Thermo Fisher Scientific.

Osteogenic Differentiation
For in vitro osteogenic differentiation assay, mandibular MSCs were cultured under
osteogenic conditions in a medium containing 2 mM β-glycerophosphate (SigmaAldrich), 100 μM L-ascorbic acid 2-phosphate (Wako), and 10 nM dexamethasone
(Sigma-Aldrich). The osteogenic medium was changed two times a week. After 2
weeks of induction, cultured cells were harvested for Western blotting to analyze
osteogenic marker expression. For alizarin red staining, cells were induced for 4
weeks, followed by staining with alizarin red (Sigma-Aldrich) to assess mineralized
nodule formation. For the measurement of positively stained areas, NIH ImageJ
software was used. The stained area was measured in percentage of staining per
total area (% of total area).
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Adipogenic Differentiation
For in vitro adipogenesis, MSCs were cultured under adipogenic conditions. The
adipogenic inducing medium contained 500 nM isobutyl methylxanthine (SigmaAldrich), 60 μM indomethacin (Sigma-Aldrich), 500 nM hydrocortisone (SigmaAldrich), 10 μg/mL insulin (Sigma-Aldrich), and 100 nM L-ascorbic acid phosphate.
After 2 weeks of induction, cells were stained with Oil-red-O (Sigma-Aldrich) to
detect lipid-laden adipocytes. Positively stained cells were quantified under
microscope. The stained cells were measured as the percentage of stained cells
against total cells (% total cells). Cultured cells were also harvested for Western
blotting to analyze adipogenic marker expression.

Chondrogenic Differentiation
Passaged cells were pelleted (1x106 cells) in 15 mL conical polypropylene tubes,
and the pellets were cultured overnight to separate the pellets from the tube. For
chondrogenic differentiation, MSC pellets were cultured in chondrogenic induction
medium containing 10-4 M dexamethasone sodium phosphate (Sigma) and 10
ng/mL human recombinant TGF-β1 (R&D). The medium was replaced every 2 to
3 days, and cell pellets were harvested after 4 weeks of induction. Then, pellets
were lysed to collect proteins, and chondrogenic gene expression was assessed
by the Western blotting.
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Neurogenic Differentiation
For neuronal differentiation, MSCs were seeded in 2-well chamber slides (Nunc)
and cultured in DMEM/F12 (Invitrogen) supplemented with 10% FBS, 1x N-2
supplement (Life Technologies), 100 U/mL penicillin, 100 μg/mL streptomycin, 10
ng/mL fibroblast growth factor 2 (FGF2), and 10 ng/mL epidermal growth factor
(EGF) (R&D Systems) for 14 days (for Western blotting) or 21 days (for IF staining).
Medium was changed every 3 or 4 days. After induction, cells were either stained
with neurogenic markers by immunofluorescence staining or harvested to collect
proteins for Western blotting.

Western Blotting
Cells were washed with PBS and lysed in RIPA lysis buffer system with protease
and phosphatase inhibitors (Santa Cruz). Proteins were quantified using PierceTM
BCA Protein Assay Kit (Thermo scientific). 20 μg of proteins were separated by
SDS-PAGE (Invitrogen) and transferred to 0.2 μm nitrocellulose membranes
(Millipore). The membranes were then blocked with 5% non-fat dry milk and 0.1%
Tween-20 for 1 hour, followed by an overnight incubation with primary antibodies
diluted in blocking solution. The membranes were then washed and incubated for
1 hour with HRP-conjugated secondary antibody (Santa Cruz) diluted in blocking
solution. Immunoreactive proteins were detected using SuperSignal™ West Pico
PLUS Chemiluminescent Substrate, SuperSignal™ West Femto Maximum
Sensitivity Substrate (Thermo), and Autoradiography Film (Labscientific).
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Seahorse Assay
Seahorse respirometry assay was conducted in the Pancreatic Islet Cell Biology
Core at the Penn Diabetes Research Center. Prior to assay, MSCs were seeded
onto a 96-well cell culture microplate and incubated overnight to allow for metabolic
recovery after passage. On the day of assay, culture medium was replaced by
bicarbonate-free DMEM supplemented with 1mM pyruvate, 2mM glutamine, and
10mM glucose at saturating concentrations. Mitochondrial respiration, as indicated
by oxygen consumption rate (OCR; pmol/min), was monitored in real time on live
cells using a XFe96 analyzer (Agilent Technologies) before and after sequential
injections of mitochondrial modulators to evaluate the following respiratory
parameters under basal and mitochondrial stress conditions; (1) basal respiration
gauged by baseline readings; (2) ATP-coupled respiration measured after blocking
ATP synthase activity with oligomycin (1µM); (3) maximal respiration assessed by
depolarizing mitochondrial membrane potential to allow maximal electron transport
with an uncoupler, carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP;
1.5µM); (4) non-mitochondrial respiration determined by blocking mitochondrial
respiration with ETC complex inhibitors, antimycin (1µM) and rotenone (100nM);
(5) spare respiratory capacity calculated by subtracting basal respiration from
maximal respiration. Each respiratory parameter was measured 3 times (cycles)
in the following command sequence: Mix for 3 min - Wait for 2 min - Measure for
3 min - End cycle. After each assay, cells were lysed and total protein content was
quantified by BCA assay (Thermo scientific) for the normalization of data.
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siRNA Transfection
For the silencing of Oct-4 in nMSCs, we used small interfering RNAs (siRNAs)
designed to target transcript-specific regions of Oct-4 (siOct-4) and non-specific
scramble siRNAs (siControl). The siRNA constructs were purchased from Santa
Cruz. Briefly, mandibular nMSCs were isolated from C57BL/6J mice (n=2/group)
and cultured following the same protocol as previously described. Subcultured
nMSCs were transfected with siOct-4 or siControl using lipofectamine (Invitrogen)
at 70% confluence. A non-transfection control was also included to rule out the
impact by transfection conditions. The optimal siRNA concentration was
determined by transfecting nMSCs with siRNAs at different concentrations (20 µM,
50 µM, and 100 µM). siRNA-treated nMSCs were subjected to metabolic and
functional assays 1-day post-transfection. Knockdown of Oct4 was confirmed at
both RNA and protein levels before each use.

Dual Luciferase Reporter Assay
The dual luciferase reporter assay was performed following our previous protocol
(56-58). The Pgc-1α promoter 2 kb luciferase reporter was a gift from Bruce
Spiegelman (Addgene; plasmid # 8887). The reporter construct was created by
subcloning the promoter fragment containing 2 kb of 5’ flanking sequence (+78 to
-2533 from the transcription start site) of mouse Pgc-1α into the pGL3-basic vector
(Promega) (56). The Pgc-1α promoter fragment was placed upstream of the
reporter gene encoding the firefly luciferase in the pGL3-basic vector. MSCs
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cultured in 6-well plates were co-transfected with 2 μg of firefly luciferase reporter
construct and 100 ng of Renilla luciferase vector as controls for transfection
efficiency. Forty-eight hours after transfection, cells were lysed in 1x passive lysis
buffer, and the luciferase activity was measured using the Dual-Glo Luciferase
System (Promega) and a luminometer (Turner Biosystems). The luciferase (firefly)
activity was expressed as relative light units (RLU) normalized to the activity of cotransfected luciferase (Renilla).

ChIP-qPCR Assay
The ChIP-qPCR assay was performed as previously described (57,58). MSCs
grown in 10 cm cell culture dishes were fixed for 10 minutes at RT by addition of
1% PFA to the growth medium. Cells were washed twice in cold PBS
supplemented with complete protease inhibitor cocktail and gently scraped from
the plate. Cell lysis and chromatin immunoprecipitation were performed using the
ChIP Assay Kit (Millipore). For chromatin fragmentation, cells were sonicated using
a Branson Sonifier 450 on power setting 4 in 30 seconds bursts with 1 minute
cooling on ice for a total sonication time of 4 minutes. For immunoprecipitations,
1:100 dilution of Oct-4 antibody was used to capture protein-DNA complexes, and
isotype-matched IgG was used as negative control. All resulting precipitated DNA
samples were quantified with real-time PCR and expressed as the percentage of
input DNA.
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Statistics
To determine the number of specimens for the proposed experiments, power
analysis had been conducted based on the “Resource Equation” method because
the effect size was unknown. No animal was excluded, and mice were randomly
assigned into groups. All experiments had appropriate control groups to ensure
robust and unbiased results. These included the use of isotype controls (IgG) and
vehicle controls (control siRNA) unless otherwise indicated. Statistical analyses
were performed using the software SPSS V.26. (IBM corporation). Comparisons
between two groups were analyzed using independent two-tailed Student’s t-tests.
Comparisons between more than two groups were analyzed using one-way
ANOVA with the Bonferroni adjustment. All data shown were represented as the
mean ± standard deviation (s.d.). P values less than 0.05 were considered
statistically significant.
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Results
Neonatal and Adult MSCs Display Distinct Metabolic Profiles and Activities

The metabolic profiles of osteogenic progenitors at birth and their link to stem
cell activities during perinatal growth of craniofacial skeletal tissue are currently
unknown. Comparing distinct metabolic signatures and related cell functions
between neonatal and adult stem/progenitor cells will provide us mechanistic
insight on perinatal stem cell evolution process. Therefore, we aim to explore the
role of metabolism in regulating stem cell function in two different physiological
contexts: growth and homeostasis. For this purpose, primary neonatal (postnatal
day 1; P1) and adult (P60) MSCs were isolated from mouse mandibles and
expanded following our previously established protocol (54).

Prior to the analysis of energetic profiles of cultured MSCs, we first
characterized nMSCs and aMSCs for their morphological and functional
phenotypes. According to our preliminary data, both MSCs could form adherent
colonies that originate from a single attached cell, albeit at a different rate. In
primary culture, both MSCs displayed clonal heterogeneity which dissipated with
sequential subcultures. Even after the first passage, a typical fibroblast-like cells
started dominating colonies in both MSC populations (Fig. 7A), which led us to use
passage one cells for subsequent analyses to minimize experimental variation by
heterogenous clones while avoiding multiple passages of cell cultures that might
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affect cell properties in in vitro condition. One of the distinguishing features
between nMSCs and aMSCs was the different clonal growth rate for which nMSCs
showed faster clonal expansion, reaching over 90% confluence at day 7 in primary
culture (Fig. 7B). Consistent with this observation, the number of single-colonyinitiating clusters, termed colony forming units-fibroblasts (CFU-F), was examined
by toluidine blue staining to show a significantly greater number of colonies by over
75-fold in nMSCs (2,390 colonies per 0.2x106 cells per plate) than that in aMSCs
(32 colonies per 0.2x106 cells per plate) (Fig. 8).

Figure 7. Neonatal MSCs have similar morphology to adult MSCs but show
faster clonal expansion. (A) Microscopic images showing the size and
morphological difference between neonatal (P1) and adult (P60) mandibular MSCs.
Scale bar, 25μm. (B) Microscopic observations at day 1, day 3, and day 5 postseeding showing different clonal growth rates of neonatal (P1) and adult (P60)
mandibular MSCs. Scale bar, 500μm. ***p<0.005. Error bars: 𝑥 ± SD.
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Figure 8. Neonatal MSCs have a higher number of colony-forming cells.
Freshly isolated neonatal (P1) and adult (P60) mandibular MSCs were seeded at
different densities and evaluated for colony formation after 14 days. ***p<0.005.
Error bars: 𝑥 ± SD.

To examine whether higher clonal expansion capability is related to greater
proliferation rate in nMSCs, we then performed Ki67 immunofluorescence staining
in passage one nMSC (P1), P7MSCs (P7) and aMSC (P60) MSCs in normal culture
condition. The results showed that nMSCs displayed a substantially higher
proliferation rate than those of

P7MSCs

(by 1.5-fold) and aMSCs (by 3-fold) as

measured by the fraction of Ki67+ cells, and this rate difference was maintained for
about a month in culture, indicating that the proliferation capacities of MSCs were
not affected by our basic cell culture condition including the media constituents
(Fig. 9).
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Figure 9. Neonatal MSCs show higher proliferation rate. Immunofluorescence
staining showing Ki67+ proliferating cells in neonatal (P1), postnatal (P7), and adult
(P60) mandibular MSCs (upper panels: staining performed 1 day after seeding
50,000 cells, lower panels: staining performed 3.5 weeks after seeding 20,000
cells). Scale bar, 25μm. **p<0.01. Error bars: 𝑥 ± SD.

Next, we compared the multilineage differentiation potential between the MSC
groups. Under osteogenic culture conditions, nMSCs showed four-fold increased
formation of mineralized nodule compared to P7MSCs and aMSCs (Fig. 10A). The
expression levels of osteogenic markers, runt-related transcription factor 2 (Runx2)
and alkaline phosphatase (Alp), were also elevated in nMSCs than those in
P7MSCs

and aMSCs (Fig. 10B). Similarly, under adipogenic culture conditions,

nMSCs had a superior capacity to differentiate into Oil-red-O-positive lipid-laden
adipocytes (over 2.5-fold increase in adipocyte numbers than other MSC groups)
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with a corresponding increase in expression of adipogenic markers, peroxisome
proliferator-activated receptor gamma (Ppar-𝛾) and lipoprotein lipase (Lpl), when
compared to

P7MSCs

and aMSCs (Fig. 11). Moreover, nMSCs showed higher

expressions of neurogenic markers such as Nestin and β 3-tubulin under
neurogenic culture conditions (>15% more neuronal cells than other MSC groups),
as well as chondrogenic markers, collagen type 2 (Col2) and aggrecan (Acan)
under chondrogenic culture conditions, than those in P7MSCs and aMSCs (Fig. 12).

Figure 10. Neonatal MSCs display enhanced osteogenic capacity. (A) Alizarin
red staining showing mineralized nodule formation. MSCs were cultured in
osteogenic differentiation medium for 21 days. (B) Western blotting showing the
expression levels of osteogenic genes Runx2 and Alp in neonatal (P1), postnatal
(P7), and adult (P60) mandibular MSCs after cultured in osteogenic differentiation
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medium for 14 days. β-Actin was used as a loading control. **p<0.01. Error bars:

Neonatal MSC

P7 MSC

B

40

**

**

30
20
10
0
Ne
M ona
SC ta
(P1 l
)
P
M 7
SC
(P7
)
A
M du
SC lt
(P6
0)

A

Oil red O + cells (per area)

𝑥 ± SD.

PPAR!
Adult MSC

LPL

M P7
SC
(P7
)
A
M du
SC lt
(P6
0)

Ne
M ona
SC ta
(P1 l
)

β-Actin

Figure 11. Neonatal MSCs exhibit increased adipogenic capacity. (A) Oil-redO staining showing lipid-laden adipocytes in neonatal (P1), postnatal (P7), and
adult (P60) mandibular MSCs. MSCs were cultured in adipogenic differentiation
medium for 14 days. (B) Western blotting showing the expression levels of
adipogenic factors PPAR𝛾 and LPL in neonatal (P1), postnatal (P7), and adult (P60)
mandibular MSCs after cultured in adipogenic differentiation medium for 14 days.
β-Actin was used as a loading control. **p<0.01. Error bars: 𝑥 ± SD.
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Figure 12. Neonatal MSCs display enhanced neurogenic and chondrogenic
differentiation potential. (A) Immunofluorescence staining showing Nestin+, β3tubulin+ or NeuN+ neuronal cells in neonatal (P1), postnatal (P7), and adult (P60)
mandibular MSCs. MSCs were cultured in neurogenic differentiation media for 21
days. (B) Western blotting showing the expression levels of neurogenic (NeuN,
β3-tubulin) and chondrogenic (Col2, Acan) markers in neonatal (P1), postnatal
(P7), and adult (P60) mandibular MSCs after cultured in neurogenic and
chondrogenic differentiation medium for 14 days. β-Actin was used as a loading
control. *p<0.05 and **p<0.01. Error bars: 𝑥 ± SD.
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Collectively, our data indicated that cultured nMSCs exhibited functional
robustness commensurate with their physiological role during perinatal growth.
However, the observed phenotypic differences between nMSCs and aMSCs could
be present because of a considerable chronological gap (60 days) between two
MSC populations and not because of abrupt environmental changes occurring
during early postnatal development. To rule out this possibility, we also examined
proliferation and multilineage differentiation capabilities of MSCs at postnatal day
7 (P7MSCs). Interestingly, the aforementioned parameters for proliferation and
multilineage differentiation potential in

P7MSCs

were rather close to those shown

in aMSCs, suggesting the significant decline of MSC properties may occur during
perinatal stem cell transition (Fig. 9-12).

To gain insight into the mechanisms that control the molecular switch for stem
cell transition, we then performed RNA-sequencing (RNA-seq) analysis (59,60) to
compare transcriptomic profiles between nMSCs and aMSCs cultured in normal
medium. We found 3,465 transcripts that significantly change their expression
between nMSCs and aMSCs (log2 fold change (FC) > 1 and FC < -1 and P value
< 0.05) (Fig. 13A). Among these, 2,122 (61.2%) were down-regulated and 1,343
(38.8%) up-regulated in nMSCs (Fig. 13B-D). Gene ontology (GO) enrichment
analysis over top 1,000 differentially expressed genes (DEGs) showed that the
most enriched were associated with translation and OxPhos categories (Fig. 13E),
suggesting the mitochondrial respiration as the potential metabolic switch that
supports the robust activities of nMSCs.
35

36

Figure 13. Transcriptome analysis of neonatal and adult MSCs. (A) Heat maps
depicting differentially expressed genes (DEGs) between nMSCs and aMSCs.
Gene expression is shown in normalized log2 counts per million. DEGs were
selected based on the fold change. (B, C) Volcano plot with statistical analysis.
The log2 fold changes in gene expression between nMSCs and aMSCs were
presented on x-axis and the statistical significance (p-value) was presented on the
y-axis. (D) Venn diagram illustrating DEGs between nMSCs and aMSCs (P < 0.05).
(E) Gene ontology (GO) terms enriched over top 1,000 DEGs. Only the top 20
biological processes were listed (FDR < 0.05).

Then, we categorized the DEGs by stem cell and lineage-specific markers to
examine if these genes are highly expressed in nMSCs to enhance stem cell
properties. We identified 68 MSC-related genes that significantly change their
expression between nMSCs and aMSCs. Among them, 27 (39.8%) were
downregulated and 41 (60.2%) were upregulated in nMSCs (Fig. 14A), suggesting
that nMSCs have more active stem cell features. We further confirmed this finding
by RT-qPCR and found that expression levels of known MSC (Pdgfrb, Prrx1,
CD146, Nanog, and Sox2) and differentiation (Runx2, Col1a1, Col2a1, and Acan)
markers were markedly increased in nMSCs than in aMSCs (Fig. 14B). GO
enrichment analysis showed that genes upregulated in nMSCs (log2 FC > 1)
clustered in biological processes involving extracellular matrix organization and
mesenchyme development (Fig. 14C). Since we hypothesized that Oct-4 plays a
crucial role in nMSC function, we also evaluated the expression level of this stem
cell marker. As we expected, both RNA and protein levels of Oct-4 were
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significantly elevated in nMSCs (RNA increased by 5-fold) compared to aMSCs
(Fig. 14D).

Figure 14. Transcriptome analysis shows higher expression levels of stem
cell and differentiation markers in neonatal MSCs. (A) Heat maps depicting
differential expression of stem cell and lineage-specific genes between nMSCs
and aMSCs. (B) qPCR assay showing significantly higher levels of MSC and
differentiation marker expression in nMSCs than in aMSCs. *p<0.05. Error bars: 𝑥
± SD. (C) GO enrichment analysis for DEGs upregulated in nMSCs listing top 20
biological processes including extracellular matrix organization and mesenchyme
development (FDR <0.05). (D) qPCR and western blotting analysis showing
expression levels of Oct-4 in nMSCs and aMSCs. **p<0.01. Error bars: 𝑥 ± SD.
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Since our in vitro data showed faster clonal expansion and higher proliferation of
nMSC in culture (Fig. 15B), we examined the differential expression of cell cycle
genes between nMSCs and aMSCs. Out of 66 DEGs in the cell cycle category, 31

nMSCs
display
proliferation
rate
(47%) were
downregulated
and 35higher
(53%) were
upregulated in nMSCs
(Fig. 15A).
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Figure 15. Neonatal MSCs display higher proliferation rate. (A) Heat maps
depicting differential expression of cell cycle-related genes between nMSCs and
aMSCs. (B) Immunofluorescence staining showing increased Ki67+ proliferating
cells in nMSCs compared to aMSCs (staining performed 1 day after seeding
50,000 cells), Scale bar, 25 µm. **p<0.01. Error bars: 𝑥 ± SD.
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As our earlier GO term analysis indicated that DEGs were enriched for OxPhos in
nMSCs (Fig. 13E), we decided to further investigate metabolic pathways in our
RNAseq data. We identified genes related to TCA cycle and mitochondria to be
significantly overrepresented in nMSCs (Fig. 16A). Gene set enrichment analysis
(GSEA) on RNA-seq data further confirmed this finding by showing enrichment for
mitochondrial metabolism and anabolic pathway genes (i.e., TCA cycle,
oxocarboxylic acid metabolism, and cholesterol synthesis) in nMSCs (Fig. 16B).
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Figure 16. Transcriptome analysis shows robust expression of genes related
to mitochondrial metabolism in neonatal MSCs. (A) Heat maps depicting
differential expression of TCA cycle and mitochondria-related genes between
nMSCs and aMSCs. (B) Gene set enrichment analysis (GSEA) showing
enrichment for mitochondrial metabolism and anabolic pathway genes in nMSCs.

As our RNA-seq data demonstrated the marked upregulation of mitochondrial
metabolism related genes in nMSCs, we evaluated the expression level of the key
mitochondrial regulator Pgc-1α by RT-qPCR and western blotting analyses. Both
transcript and protein levels of Pgc-1α were shown to be significantly higher in
nMSCs (RNA increased by 10-fold) than in aMSCs, and this expression pattern
was positively correlated with the expression levels of Oct-4, suggesting potential
interplay between these metabolic and pluripotency factors (Fig. 17A). To further
confirm our findings, we performed immunofluorescence staining on neonatal and
adult MSCs and mandibular sections using antibodies for Pgc-1α and Oct-4. As
expected, the protein levels of Pgc1α and Oct-4 were significantly increased in
nMSCs (over 10-fold) and neonatal mandibles (P1) (over 4- to 5-fold) when
compared to the adult counterparts (P60) (Fig. 17B, C). We also stained MSCs in
situ on mandibular sections using the antibody for MSC marker Sca-1 and
observed that the number of MSCs were significantly higher in neonatal mandibles
(P1) than in adult mandibles (P60) (Fig. 17C).
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Figure 17. The expression levels of Pgc-1α and Oct4 are significantly
elevated in neonatal MSCs and neonatal mandibles (P1). (A) RT-qPCR and
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western blotting analyses showing higher expression levels of Oct-4 and Pgc-1α
in nMSCs. (B) Immunofluorescence staining using Pgc-1α and Oct-4 antibodies
showing higher protein levels of Pgc-1α and Oct-4 in nMSCs. (C) Double
immunofluorescence staining for Pgc-1α or Oct-4 with MSC marker Sca-1 showing
a higher number of MSCs as well as Pgc-1α and Oct-4 protein levels in neonatal
mandibles (P1). Scale bar, 25 µm, n=6, *p<0.05 and **p<0.01. Error bars: 𝑥 ± SD.

To validate if MSC’s metabolic status inferred from differential gene
expression patterns would reflect actual metabolic differences between nMSCs
and aMSCs, we performed the Seahorse assay which measures oxygen
consumption rate (OCR) as a proxy for OxPhos activity in real time on live cells.
As expected, nMSCs showed significantly higher rates of basal (>67%), ATPcoupled (>37%), and maximal respiration (>43%) than aMSCs, indicating that
robust mitochondrial metabolism supports nMSCs (Fig. 18). In addition, nMSCs
had greater spare respiratory capacity (>67%) than aMSCs, indicating that nMSCs
are well primed for the increasing energy demand (Fig. 18).
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Figure 18. Neonatal MSCs exhibit robust mitochondrial respiration. Oxygen
consumption rate (OCR; pmol/min) in nMSCs and aMSCs measured by Seahorse
assay. MSCs were incubated with assay media containing 1mM pyruvate, 2mM
glutamine, and 10mM glucose at saturating concentrations during the assay. OCR
was monitored before and after sequential injections of mitochondrial modulators
to evaluate the following respiratory parameters under basal and mitochondrial
stress conditions; (1) basal respiration gauged by baseline readings; (2) ATPcoupled respiration measured after blocking ATP synthase activity with oligomycin
(1µM); (3) maximal respiration assessed by depolarizing mitochondrial membrane
potential to allow maximal electron transport with an uncoupler, carbonyl cyanide4-(trifluoromethoxy) phenylhydrazone (FCCP; 1.5µM); (4) non-mitochondrial
respiration determined by blocking mitochondrial respiration with ETC complex
inhibitors, antimycin (1µM) and rotenone (100nM); (5) spare respiratory capacity
calculated by subtracting basal respiration from maximal respiration. n=6, *p<0.05.
Error bars: 𝑥 ± SD.

In line with this, RT-qPCR showed significantly higher expression levels of key
TCA cycle enzymes including citrate synthase (CS) and isocitrate dehydrogenase
3a (Idh3a) (by 2- to 4-fold) as well as electron transport chain (ETC) complex genes
(by 1.3- to 3-fold) in nMSCs compared to aMSCs, further supporting robust
OxPhos activity in nMSCs (Fig. 19). We also evaluated the expression levels of
key flux-controlling enzymes in glycolysis by RT-qPCR to compare glycolytic
profiles between nMSCs and aMSCs. All glycolytic genes including glucose
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Figure 19. Both OxPhos and glycolysis genes are significantly upregulated
in neonatal MSCs. RT-qPCR analysis showing relative expression levels of
OxPhos genes including TCA cycle (CS and Idh3a) and ETC complex subunits
(Ndufs2, Ndufv2, Uqcrfs1, Cox15, Cox6a2, Atp5d, Atp5h, Atp6v1g2, and Atp8b2)
in nMSCs and aMSCs. In addition, the expression levels of key glycolytic enzymes
(Glut1, Ldha, and Pfk1) were also evaluated in both MSC groups. n=3, **p<0.01,
***p<0.005. Error bars: 𝑥 ± SD.

We also evaluated the protein expression levels of glycolysis (Glut1 and Ldha) and
OxPhos (CS and Idh3a) enzymes in cultured MSCs and mandibular specimens
obtained from neonatal and adult mice by immunofluorescence staining. Mandible
sections were co-stained with the MSC marker Sca-1 to demarcate the MSC
population in situ. In consistent with their transcript levels, the protein expression
levels of all analyzed metabolic enzymes were shown to be significantly higher in
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nMSC (by 5- to 10-fold) (Fig. 20) and neonatal mandibles (by 7- to 12-fold) (Fig.
21) than in their adult counterparts, indicating a robust metabolic status of nMSCs
in which both glycolysis and OxPhos are active.

Figure 20. Both glycolysis and OxPhos enzymes are significantly
upregulated in neonatal MSCs. Immunofluorescence staining using antibodies
for glycolysis (Glut1 and Ldha) and TCA cycle (CS and Idh3a) enzymes in nMSCs
and aMSCs cultured under normal conditions. Images showing higher protein
levels of both metabolic pathway enzymes in nMSCs than in aMSCs. Scale bar,
25 µm. n=3, ***p<0.005. Error bars: 𝑥 ± SD.
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Figure 21. Both glycolysis and OxPhos enzymes are significantly
upregulated in neonatal mandibles. Double immunofluorescence staining using
antibodies for glycolysis (Glut1 and Ldha) or TCA cycle (CS and Idh3a) enzymes
in neonatal (P1) and adult (P60) mandibles. Mandible sections were co-stained
with Sca-1 to mark MSC populations. Images showing higher protein levels of both
metabolic pathway enzymes in neonatal mandible. Scale bar, 25 µm. n=3,
***p<0.005. Error bars: 𝑥 ± SD.

Overall, our data indicate that nMSCs are functionally robust, equipped with higher
proliferation and differentiation capacities, and fueled by a bivalent energy program
in which both glycolysis and OxPhos are highly activated.
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Pgc-1α is Required for Mitochondrial Metabolism and Stem Cell Function

Since Pgc-1α is a strong inducer of mitochondrial metabolism, we
hypothesized that Pgc-1α depletion adversely affects mitochondrial respiration and
stem cell activity of nMSCs. To test this, we isolated nMSCs from mandibles of
newborn Pgc-1α-/- mice and WT littermates. We found that colony size and number
were not different between WT and Pgc1α-/- nMSCs in primary culture (Fig. 22A).
To examine whether Pgc-1α deletion affects MSC metabolism, we screened
metabolic status of each MSC group by MTT assay. The assay measures
NAD(P)H-dependent reductase activity as a surrogate for cell’s metabolic activity.
As expected, loss of Pgc-1α in nMSCs significantly reduced metabolic activity (by
2-fold) compared to WT littermates (Fig. 22B). In contrast, Pgc-1α deletion in
aMSCs greatly enhanced the activity of NAD(P)H-dependent enzyme (by 5-fold)
compared to WT aMSCs, which might be attributable to a compensatory increase
in cellular redox program in response to the oxidative stress caused by Pgc-1α
loss (Fig. 22B).
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Figure 22. Pgc1α-/- nMSCs have a similar morphology and colony size to WT
nMSCs but show decreased cellular metabolic activity. (A) Microscopic
images showing no morphology and colony size difference between WT and
Pgc1α-/- nMSCs. Scale bar, 25um. (B) MTT assay performed to assess metabolic
activities of each MSC group cultured under normal conditions. Pgc-1α deletion
reduced the metabolic activity of nMSCs as measured by NAD(P)H-dependent
reductase activity. n=6, ***p<0.005. Error bars: 𝑥 ± SD.

To determine whether the loss of Pgc-1α entails functional alterations in nMSCs,
we assessed the proliferation and multilineage differentiation potential of WT and
Pgc1α-/- nMSCs. Immunofluorescence staining using Ki67 antibody showed that
depletion of Pgc-1α reduced cell proliferation rate of nMSCs (by 3-fold) (Fig. 23).

Figure 23. Pgc1α-/- nMSCs display decreased cell proliferation rate. Ki67
immunofluorescence staining showing decreased Ki67+ cells in Pgc1α-/- nMSCs
compared to WT cells. Scale bar, 25 µm. n=3, ***p<0.005. Error bars: 𝑥 ± SD.
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Then, we evaluated osteogenic differentiation potential between WT and Pgc1α-/nMSCs. Under osteogenic culture conditions, Pgc1α-/- nMSCs showed significantly
reduced formation of mineralized nodule (by 3-fold) as well as decreased
expression levels of osteogenic markers, Runx2 and Alp than those in WT group
(Fig. 24). Similarly, upon adipogenic induction, Pgc1α-/- nMSCs had a decreased
capacity to differentiate into Oil-red-O-positive lipid-laden adipocytes (80%
decrease in adipocyte numbers) with a corresponding decrease in the expression
of adipogenic markers, Ppar- 𝛾 and Lpl, compared to WT nMSCs (Fig. 25),
indicating nMSC functions are significantly compromised by the loss of Pgc-1α.

Figure 24. Pgc1α-/- nMSCs show reduced osteogenic capacity. Alizarin red
staining showing mineralized nodule formation. MSCs were cultured in osteogenic
differentiation medium for 21 days. RT-qPCR showing the expression levels of
osteogenic genes (Runx2 and Alp) in WT and Pgc1α-/- nMSCs. Gapdh was used
for internal control. n=3, *p<0.05, ***p<0.005. Error bars: 𝑥 ± SD.
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Figure 25. Pgc1α-/- nMSCs exhibit reduced adipogenic capacity. Oil-red-O
staining showing lipid-laden adipocytes in WT and Pgc1α-/- nMSCs. nMSCs were
cultured in adipogenic differentiation media for 14 days. RT-qPCR showing the
expression levels of adipogenic markers Ppar-𝛾 and Lpl in WT and Pgc1α-/- nMSCs.
Gapdh was used for internal control. n=3, *p<0.05, ***p<0.005. Error bars: 𝑥 ± SD.

To investigate whether the functional decline of nMSCs by Pgc-1α deletion
accompanies metabolic changes in nMSCs, we performed the Seahorse assay to
compare mitochondrial OxPhos between WT and Pgc1α-/- nMSCs. Indeed, the
loss of Pgc-1α in nMSCs caused significantly lower rates of basal (<40%), ATPcoupled (<43%), and maximal respiration (<47%) than those of WT control. In
addition, Pgc1α-/- nMSCs had a significant reduction in spare respiratory capacity
(<55%) than WT nMSCs, indicating mitochondrial respiration was significantly
compromised in nMSCs by the loss of Pgc-1α (Fig. 26).
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was monitored before and after sequential injections of mitochondrial modulators
to evaluate the following respiratory parameters under basal and mitochondrial
stress conditions; (1) basal respiration: baseline readings; (2) ATP-coupled
respiration: oligomycin (1µM); (3) maximal respiration: FCCP (1.5µM); (4) nonmitochondrial respiration: antimycin (1µM) and rotenone (100nM); (5) spare
respiratory capacity: maximal - basal respiration. n=6, *p<0.05. Error bars: 𝑥 ± SD.

Consistent with this finding, the expression levels of select mitochondria-related
genes including TCA cycle enzymes (CS and Idh3a) and ETC subunits were
significantly downregulated (by 10-40%) in Pgc1α-/- nMSCs compared to WT
control, indicating reduced OxPhos activity by Pgc-1α deletion (Fig. 27).
Unexpectedly, the expression levels of key glycolytic enzymes (Glut1, Ldha, and
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Pfk1) were also significantly decreased (by 10-40%) in Pgc1α-/- nMSCs than in WT
nMSCs, indicating that there was no compensatory increase of glycolysis followed
by the impaired mitochondrial OxPhos in Pgc1α-/- nMSCs (Fig. 27).

Figure 27. Both OxPhos and glycolysis genes are significantly reduced in
Pgc1α-/- nMSCs. RT-qPCR analysis showing relative expression levels of OxPhos
genes including TCA cycle (CS and Idh3a) and ETC complex subunits (Ndufs2,
Ndufv2, Uqcrfs1, Cox15, Cox6a2, Atp5d, Atp5h, Atp6v1g2, and Atp8b2) in WT and
Pgc1α-/- nMSCs. The expression levels of key glycolytic enzymes (Glut1, Ldha,
and Pfk1) were also evaluated in both MSC groups. n=3, *p<0.05, **p<0.01. Error
bars: 𝑥 ± SD.

We also compared the protein expression levels of key glycolysis (Glut1 and Ldha)
and OxPhos (CS and Idh3a) enzymes in WT and Pgc1α-/- nMSCs by
immunofluorescence staining. In consistent with their transcript levels, the protein
expression levels of all analyzed metabolic enzymes were shown to be significantly
lower (by 70-90%) in Pgc1α-/- nMSCs than in WT control, indicating that both
glycolysis and OxPhos are impaired by the loss of Pgc-1α (Fig. 28).
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Figure 28. Both glycolysis and OxPhos enzymes are significantly decreased
in Pgc1α-/- nMSCs. Immunofluorescence staining using antibodies for glycolysis
(Glut1 and Ldha) and TCA cycle (CS and Idh3a) enzymes in WT and Pgc1α-/nMSCs cultured under normal conditions. Images showing lower protein levels of
both metabolic pathway enzymes in Pgc1α-/- nMSCs compared to WT control.
Scale bar, 25 µm. n=3, ***p<0.005. Error bars: 𝑥 ± SD.

Collectively, these data demonstrate that Pgc-1α is required for proper nMSC
metabolism and robust proliferation and differentiation capabilities.
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Oct-4 Regulates Pgc-1α-OxPhos-driven Metabolism and Function of MSCs

Given the significant upregulation of Pgc-1α and Oct-4 expression in nMSCs
and the presence of putative Oct-4 binding motifs on the Pgc-1α promoter region,
we hypothesized that Oct-4 regulates the Pgc-1α expression and the related
cellular metabolism and functions. To address this hypothesis, we used small
interfering RNA (siRNA) targeting transcript-specific regions of Oct-4 to silence
Oct-4 expression in nMSCs. To determine an optimal siRNA concentration for Oct4 silencing, we transfected nMSCs with 100 µM (siOct4-1), 50 µM (siOct4-2), and
20 µM (siOct4-3) siOct-4 and control siRNAs (siControl1-3). A non-transfection
control was included to show that our transfection condition did not affect Oct-4
silencing. RT-qPCR confirmed that 100 µM siOct-4 (siOct4-1) had the best
silencing efficiency to achieve 50% reduction of Oct-4 expression (Fig. 29A).

To investigate whether Oct-4 downregulation could alter nMSC functions, we
assessed proliferation and multilineage differentiation capacities of siOct-4-treated
and control nMSCs. Ki67 IF staining showed that downregulation of Oct-4
significantly reduced the proliferation rate of nMSCs (by >50%) (Fig. 29B).
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Figure 29. Oct-4 knockdown in nMSCs decreased cell proliferation rate. (A)
RT-qPCR showing Oct-4 knockdown efficiency at different siRNA concentrations
(siOct4-1: 100 µM, siOct4-2: 50 µM, siOct4-3: 20 µM). Non-specific scramble
siRNAs were served as siControl. Non-transfection controls were also included to
rule out any impact by transfection conditions. (B) Ki67 immunofluorescence
staining showing decreased Ki67+ cells in siOct-4-treated nMSCs compared to
siControl group. Scale bar, 25 µm. n=3, *p<0.05, ***p<0.005. Error bars: 𝑥 ± SD.

Next, we compared the multilineage differentiation potential between siOct-4 and
siControl treated nMSCs. Under osteogenic culture conditions, siOct-4 treated
nMSCs showed reduced mineralized nodule formation (by 50%) and lower
expression levels of osteogenic markers (Runx2 and Alp) than the control group
(Fig. 30). Likewise, under adipogenic culture conditions, siOct-4 treated nMSCs
had a decreased capacity to differentiate into Oil-red-O-positive lipid-laden
adipocytes (by 70%) with a corresponding decrease in the expression of
adipogenic markers (Ppar-𝛾 and Lpl) compared to the control group (Fig. 31).
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Figure 30. Oct-4 knockdown nMSCs show reduced osteogenic capacity.
Alizarin red staining showing mineralized nodule formation. nMSCs were cultured
in osteogenic differentiation medium for 21 days (for Alizarin red staining) or 14
days (for RT-qPCR). RT-qPCR showing the expression levels of osteogenic genes
(Runx2 and Alp) in siOct-4 and siControl treated nMSCs. Gapdh was used as an
internal control. n=3, *p<0.05, **p<0.01, ***p<0.005. Error bars: 𝑥 ± SD.

Figure 31. Oct-4 knockdown nMSCs exhibit decreased adipogenic capacity.
Oil-red-O staining showing lipid-laden adipocytes in siOct-4 and siControl treated
nMSCs. nMSCs were cultured in adipogenic differentiation medium for 14 days.
RT-qPCR showing the expression levels of adipogenic factors (Ppar𝛾 and Lpl) in
siOct-4 and siControl treated nMSCs. Gapdh was used as an internal control. n=3,
*p<0.05, **p<0.01, ***p<0.005. Error bars: 𝑥 ± SD.
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To determine whether Oct-4 downregulation could affect nMSC metabolism,
the Seahorse assay was performed to evaluate mitochondrial OxPhos in siOct-4
and siControl treated nMSCs. Consistent with the OxPhos decline in nMSCs by
Pgc-1α deletion, Oct-4 downregulation phenocopied Pgc1α-/- nMSCs by impairing
mitochondrial respiration with significantly lower rates of basal (<43%), ATPcoupled (<43%), maximal respiration (<47%), and spare respiratory capacity
(<55%) in siOct-4 treated nMSCs than in the control group (Fig. 32).
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were subjected to the Seahorse assay. Cells were incubated in assay media
containing 1mM pyruvate, 2mM glutamine, and 10mM glucose at saturating
concentrations during the assay. OCR was monitored before and after sequential
injections of mitochondrial modulators to evaluate the following respiratory
parameters under basal and mitochondrial stress conditions; (1) basal respiration:
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baseline readings; (2) ATP-coupled respiration: oligomycin (1µM); (3) maximal
respiration: FCCP (1.5µM); (4) non-mitochondrial respiration: antimycin (1µM) and
rotenone (100nM); (5) spare respiratory capacity: maximal - basal respiration. n=6,
*p<0.05. Error bars: 𝑥 ± SD.

Consistent with this, the expression levels of select OxPhos genes including TCA
cycle enzymes (CS and Idh3a) and ETC subunits were significantly decreased (by
15-57%) in siOct-4 treated nMSCs compared to those in siControl group, further
confirming the impaired OxPhos activity in nMSCs by Oct-4 downregulation (Fig.
33). Further, the expression levels of key glycolytic enzymes (Glut1, Ldha, and
Pfk1) were significantly reduced (by 16-45%) in siOct-4 treated nMSCs than in
siControl nMSCs, indicating that there was no compensatory increase of glycolysis
in response to the impaired mitochondrial OxPhos by Oct-4 knockdown (Fig. 33).

Figure 33. Both OxPhos and glycolysis genes are downregulated in Oct-4
knockdown nMSCs. RT-qPCR analysis showing relative expression levels of
OxPhos genes including TCA cycle (CS and Idh3a) and ETC complex subunits
(Ndufs2, Ndufv2, Uqcrfs1, Cox15, Cox6a2, Atp5d, Atp5h, Atp6v1g2, and Atp8b2)
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in siOct-4 and siControl treated nMSCs. The expression levels of key glycolytic
enzymes (Glut1, Ldha, and Pfk1) were also evaluated in both nMSC groups. n=3,
*p<0.05, **p<0.01, ***p<0.005. Error bars: 𝑥 ± SD.

We also compared the protein expression levels of key glycolysis (Glut1 and Ldha)
and OxPhos (CS and Idh3a) enzymes in siOct-4 and siControl treated nMSCs by
immunofluorescence staining. In agreement with their transcript levels, the protein
expression levels of all analyzed metabolic enzymes were significantly reduced
(by 70-93%) in siOct-4 treated nMSCs than those in siControl group, indicating that
both glycolysis and OxPhos are impaired by Oct-4 downregulation (Fig. 34).
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Figure 34. Both glycolysis and OxPhos proteins are decreased in Oct-4
knockdown nMSCs. Immunofluorescence staining using antibodies for glycolysis
(Glut1 and Ldha) and TCA cycle (CS and Idh3a) enzymes in siOct-4 and siControl
treated nMSCs cultured under normal conditions. Images showing lower protein
levels of both metabolic pathway enzymes in siOct-4 treated nMSCs compared to
siControl group. Scale bar, 25 µm. n=3, ***p<0.005. Error bars: 𝑥 ± SD.

Overall, the data indicate that Oct-4/Pgc-1α axis is required for the proper
metabolism of nMSCs to support their robust proliferation and differentiation
abilities.

Given that the expression patterns of Pgc-1α and Oct-4 in nMSCs and aMSCs
showed a positive correlation (Fig. 17) and that Oct-4 binding motifs could be
predicted on the Pgc-1α promoter region (Fig. 36B), we reasoned that Oct-4 could
act as a potential upstream regulator to control Pgc-1α expression. To test this
possibility, we first performed RT-qPCR analysis to show Pgc-1α KO did not affect
Oct-4 expression levels, while Oct-4 knockdown by siRNA treatment significantly
reduced Pgc-1α expression levels (by 20%) (Fig. 35A). In addition, IF staining
further confirmed that Pgc-1α KO did not affect Oct-4 protein levels, whereas Oct4 knockdown by siRNA significantly decreased Pgc-1α protein levels with over 5fold difference, indicating that Oct-4 acts upstream of Pgc-1α (Fig. 35B).
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Figure 35. Oct-4 acts upstream of Pgc-1α in nMSCs. (A) RT-qPCR analysis
showing that Pgc-1α KO did not affect Oct-4 expression levels. In contrast, Oct-4
knockdown by siRNA treatment significantly reduced Pgc-1α expression levels. (B)
Immunofluorescence staining showing that Pgc-1α KO did not affect Oct-4 protein
levels, while Oct-4 knockdown by siRNA significantly reduced Pgc-1α protein
levels. n=3, *p<0.05, ***p<0.005. Error bars: 𝑥 ± SD.
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These data prompted us to further investigate whether Oct-4 acts as a transcription
factor to directly bind on Pgc-1α promoter and regulate Pgc-1α expression. First,
we performed a dual luciferase reporter assay to determine the responsiveness of
Pgc-1α promoter to Oct-4. We used a reporter construct in which the promoter
fragment containing 2 kb of 5’ flanking sequence (+78 to -2533 from the
transcription start site) of mouse Pgc-1α was subcloned upstream of the reporter
gene encoding the firefly luciferase in the pGL3-basic vector (56). Thus, the
expression of luciferase gene was under direct control of the Pgc-1α promoter. We
observed the Pgc-1α promoter activity to be significantly increased (by 40%) in
nMSCs compared to aMSCs (Fig. 36A). To address if the induction of reporter
activity could be attributed to the level of Oct-4, we performed the reporter assay
in siOct-4 and siControl treated nMSCs. Indeed, the Pgc-1α promoter activity was
significantly attenuated (by 20%) in siOct-4 treated nMSCs, indicating that Pgc-1α
promoter is subject to positive regulation by Oct-4 (Fig. 36A).
To investigate whether Oct-4 could be recruited and bind to the Pgc-1α promoter,
we then performed a chromatin immunoprecipitation with quantitative PCR (ChIPqPCR) assay. Prior to assay, putative Oct-4 binding motifs were identified within
the 2 kb Pgc-1α promoter region using an in silico analysis (Fig. 36B). Based on
this prediction, primers were designed for qPCR to determine if these predicted
Oct-4 binding sites are enriched by immunoprecipitation. Out of eleven candidate
Oct-4 binding sites, the ChIP-qPCR data showed enrichment of Oct-4 at the fourth
site within the Pgc-1α promoter, but not at the other sites in nMSCs and aMSCs
(Fig. 36B). Oct-4 occupancy at this site was significantly higher (by 3-fold) in
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nMSCs than in aMSCs, and siRNA-mediated depletion of Oct-4 in nMSCs resulted
in a decrease of Oct-4 enrichment (by 3-fold) to the aMSC level, indicating that
cellular Oct-4 levels affect the binding of Oct-4 to the Pgc-1α promoter and the
induction of the promoter activity (Fig. 36B). To exclude non-specific binding of
Oct-4 antibody, we included an antibody pull-down control experiment (Fig. 36C).

Figure 36. Oct-4 acts as a transcription factor that directly binds to Pgc-1α
promoter and controls the promoter activity. (A) Dual luciferase reporter assay
showing the luciferase activity of the 2 kb Pgc-1α promoter fusion construct in
nMSCs, aMSCs, and siOct-4 or siControl treated nMSCs. The luciferase (firefly)
activity was expressed as relative light units (RLU) normalized to the activity of cotransfected luciferase (Renilla). (B) ChIP-qPCR assay showing the enrichment of
Oct-4 at each predicted binding site of the 2 kb Pgc-1α promoter in nMSCs, aMSCs,
and siOct-4 or siControl treated nMSCs. Data were expressed as the percentage
of input chromatin. (C) An antibody pull-down control experiment using an isotypematched IgG as a control to exclude non-specific binding of the Oct-4 antibody.
n=3, *p<0.05, **p<0.01, ***p<0.005. Error bars: 𝑥 ± SD.
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Collectively, our data strongly suggest that Oct-4 is required to regulate Pgc-1αdriven MSC metabolism and function through directly binding to the Pgc-1α
promoter and inducing the promoter activity.

Pgc-1α Plays a Pivotal Role during Craniofacial Skeletal Development

Given the robust expression of Pgc-1α in multiple neonatal tissues (40,41) and
the reduced survival rate of Pgc-1α-/- littermates during early postnatal period (39),
we reasoned that Pgc-1α exerts an integral role in developing craniofacial skeletal
tissues. To assess developmental phenotypes of craniofacial skeleton in Pgc-1α-/newborn mice, we crossed Pgc-1α+/- mice to generate Pgc-1α-/- newborn pups and
WT littermates. Consistent with the previous study (39), we observed that less than
two thirds (59%) of the Pgc-1α-/- newborn pups survived early postnatal period and
grew into adulthood (Fig. 37A). This perinatal lethality might be attributable to the
inability to maintain a normal body temperature, or the failure of cardiac maturation
given the vital roles of Pgc-1α in brown adipose and cardiac tissues (61-63).
Indeed, maintaining homozygous pups at a higher housing temperature (25°C)
could improve the survival of newborn mice. Survived Pgc-1α-/- mice displayed
growth retardation with smaller overall body size and craniofacial structures such
as mandibles than their WT counterparts (Fig. 37A). In addition, Pgc-1α-/- mice
weighed significantly less than WT littermates throughout the observation period
(from birth to the age of 2 months), indicating the important role of Pgc-1α during
normal postnatal growth (Fig. 37B).
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Figure 37. Pgc-1α-/- mice display postnatal growth retardation. (A) Pgc-1α-/newborn pups showing perinatal lethality, reduced overall body size, and smaller
craniofacial structures including mandibles compared to WT mice. (B) The body
weight measurement during the postnatal growth period showing significantly
lower weights of Pgc-1α-/- mice than WT mice. n=10 for each group. #p<0.005
between Het and KO male mice. *p<0.005 between Het and KO female mice.
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For a quantitative evaluation of craniofacial skeletons, we employed bone
histomorphometry approaches including micro-CT and histology. First, the
variations in overall morphology and developmental patterns of craniofacial bones
were assessed in Pgc-1α-/- and WT newborn pups using a micro-CT scan. Though
we did not detect significant craniofacial dysmorphism or skeletal anomalies
associated with Pgc-1α deficiency, we observed overall undersized craniofacial,
axial, and appendicular bones in Pgc-1α-/- newborn mice (Fig. 38A-C). The microCT analysis showed that the size of mandibles from Pgc-1α-/- newborn pups was
significantly reduced (by 30%) compared to WT littermates (Fig. 38A, B).
Interestingly, we found open mid-palatal sutures in Pgc-1α-/- neonates, indicating
the potential involvement of Pgc-1⍺ in normal palate development (Fig. 38B). To
address if the developmental defects are specific to craniofacial bones or they are
also present in other skeletal tissues of Pgc-1α-/- newborn mice, we measured the
bone mineral density (BMD) of femurs obtained from Pgc-1α-/- and WT neonates.
Notably, the femoral BMD of Pgc-1α deficient newborns was significantly lower (by
63%) than that of WT littermates, indicating that Pgc-1α deletion globally affects
different skeletal tissues irrespective of their embryonic origins and ossification
types (Fig. 38C).
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Figure 38. Pgc-1α-/- neonates show depauperate skeletal phenotypes. MicroCT analysis showing (A) overall undersized craniofacial bones including
mandibles, (B) open mid-palatal sutures, and (C) reduced femoral BMD (mg/cm3)
in Pgc-1α-/- newborns. Samples were scanned at 45 kVp, 177 µA, and a voxel size
of 6 µm. n=6 for each group. **p<0.01, ***p<0.005. Error bars: 𝑥 ± SD.
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To supplement the micro-CT analysis, the structures and maturation status of
craniofacial skeletal tissues were further assessed in histological preparations.
Consistent with the micro-CT data, the hematoxylin and eosin (H&E) staining of
mandibular specimens collected from Pgc-1α-/- and WT newborn pups showed that
Pgc-1α-/- newborns had significantly smaller mandibles (by around 30%) than WT
littermates (Fig. 39A). Interestingly, we found that the incisal and molar tooth germs
in Pgc-1α-/- newborns were smaller and underdeveloped compared to those in WT
littermates, suggesting a possible association between Pgc-1α deficiency and
microdontia (Fig. 39A). To evaluate the morphology and skeletal maturation of
craniofacial bones, we performed the whole-mount skeletal staining using Alcian
blue and Alizarin red which stains cartilage and bone, respectively. The wholemount staining showed that Pgc-1α-/- newborns had reduced cartilaginous tissues
in condylar areas of developing mandibles compared to their WT littermates, which
might contribute to the delayed mandibular growth in Pgc-1α-/- newborn mice (Fig.
39B).
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Figure 39. Pgc-1α-/- neonates exhibit craniofacial defects. (A) The H&E
staining showing smaller mandibles and underdeveloped tooth germs in Pgc-1α-/newborn pups. (B) The whole-mount skeletal staining showing the smaller
mandible with less cartilaginous tissues in the condyles of Pgc-1α-/- newborn mice
compared to their WT littermates. n=6 for each group. **p<0.01. Error bars: 𝑥 ± SD.

To determine if the observed skeletal phenotypes in Pgc-1α-/- neonates are
attributable to the metabolic and functional alterations of nMSCs in developing
craniofacial tissues, we performed the double immunofluorescence staining of
mandibular specimens obtained from Pgc-1α-/- and WT newborn mice using
antibodies for a proliferation marker (Ki67) and select metabolic enzymes (Glut1,
Ldha, CS, and Idh3a). Mandible sections were co-stained with the MSC marker
Sca-1 to mark stem cells in situ. Consistent with our in vitro finding (Fig. 23), IF
staining showed that the number of Sca-1+ and Ki67+ proliferating MSCs was
significantly lower (by 6-fold) in Pgc-1α-/- newborn mandibles than that in the WT

Pgc-1⍺ KO mandible show reduced tissu

counterparts (Fig. 40). In addition, the loss of Pgc-1α greatly decreased the levels
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Figure 40. The number of proliferating MSCs is significantly lower in Pgc-1αnull neonatal mandibles. Double immunofluorescence staining using antibodies
for the proliferation marker Ki67 and the MSC marker Sca-1 in Pgc-1α-/- and WT
newborn mandibles. Images showing that the number of proliferating MSCs was
greatly reduced in Pgc-1α-/- newborn mandibles. Scale bar, 25 µm. n=3, ***p<0.005.
Error bars: 𝑥 ± SD.
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Figure 41. Both glycolysis and OxPhos enzymes are significantly reduced in
MSCs of Pgc1α-/- neonatal mandibles. Double immunofluorescence staining
using antibodies for glycolysis (Glut1 and Ldha) and TCA cycle (CS and Idh3a)
enzymes in Pgc-1α-/- and WT newborn mandibles. Mandible sections were costained with Sca-1 to mark MSC populations. Images showing the lower protein
level of each metabolic pathway enzyme in Pgc-1α-/- newborn mandibles. Scale
bar, 25 µm. n=3, ***p<0.005. Error bars: 𝑥 ± SD.

Collectively, these findings illuminate the important role of Pgc-1α in modulating
the metabolic program suitable to support stem cell function for normal growth and
development of craniofacial skeletal tissues.
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Discussion
Stem cells continually acclimate to environmental vicissitudes over their life
span by shifting their metabolism and function. Upon sensing environmental
challenges and following intrinsic genetic/epigenetic programs (64-66), stem cells
rewire their metabolic scheme to accommodate the functional demands in different
physiological conditions. Still, the molecular switch regulating the cellular
energetics program remains to be elucidated. Our data demonstrate that neonatal
MSCs exhibit robust stem cell activity with higher proliferation and multilineage
differentiation potential than adult MSCS, commensurate with their roles during
perinatal growth. The vigorous activities of nMSCs are driven by the novel Oct-4controlled Pgc-1α-OxPhos metabolic switch that is turned off during the perinatal
transition to aMSCs. The failure to flick on this metabolic switch by deleting Pgc1α in nMSCs hinders normal postnatal growth and craniofacial development.

Rapidly proliferating cells such as ESCs or cancer cells employ bivalent
energetic program where mitochondrial metabolism actively shunts TCA cycle
intermediates for anabolic reactions while glycolysis quickly generates ATP for
energy and increases the flux into the pentose phosphate pathway for nucleotide
synthesis required for cell division (25-28). In the current study, we chose to study
nMSCs as they are more obtainable than ESCs and still can regenerate damaged
tissues in mice within a limited window of time after birth (up to postnatal day 7).
Similar to the metabolic profile of ESCs, nMSCs display augmented mitochondrial
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respiration with the upregulation of both TCA cycle and glycolysis genes, which
are the preferred metabolic signatures of rapidly proliferating cells. Despite the
importance of aerobic glycolysis for stem cell proliferation, the role of OxPhos in
proliferation needs careful interpretation since OxPhos drives lineage progression
of stem cells toward terminal differentiation (30). Nevertheless, as the “tuner” of
lineage progression, OxPhos can be a prime candidate switch for metabolic
reprogramming during stem/progenitor cell fate conversion.

Pgc-1α promotes mitochondrial biogenesis and respiration in neonatal liver
and heart to accommodate the increasing demand for expanded oxidative capacity
in these tissues (40,41). In agreement with this, we also observe elevated
expression of Pgc-1α in nMSCs and neonatal mandibles, which enhances OxPhos
activity by transactivating the expression of TCA cycle and ETC genes in nMSCs.
Given that the route of oxygen supply changes from fetal placenta to pulmonary
circulation as newborn starts breathing (29,30), we reason that increased tissue
oxygen tension after exposure to atmospheric oxygen at birth shifts nMSC’s
metabolic program to mitochondrial OxPhos by inducing Pgc-1α expression.
Conversely, loss of Pgc-1α in nMSCs results in decreased OxPhos which
compromises proliferation and differentiation capacities of nMSCs. Contrary to our
expectation, glycolysis genes are not upregulated by Pgc-1α deletion to
compensate for the impaired mitochondrial metabolism. Given that Pgc-1α
deletion doesn’t affect nMSC survival, we postulate that both Pgc-1α-driven
OxPhos and glycolysis need to be potentiated to satisfy the bioenergetic and
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biosynthetic requirements for the activation of nMSCs and that glycolysis alone is
not sufficient for the optimal lineage progression.

The differential expression and roles of pluripotency factors in ESCs and
somatic stem cells have been well reported in multiple studies (64,65). Though the
previous ChIP-DSL data proposed cellular metabolism and cell cycle progression
as the potential Oct-4 targets in both ESCs and MSCs (47), our study is the first to
unravel the previously unknown mechanism by which Oct-4 regulates stem cell
metabolism and activation via Pgc-1α. Using ChIP-qPCR and reporter assays, we
identify that Oct-4 directly binds to the Pgc-1α promoter and regulates its activity.
However, our data cannot corroborate whether Oct-4 regulates stem cell activity
exclusively through Pgc-1α-mediated metabolic pathway or alternative pathways
are working in parallel. Given the role of Pgc-1α as a cofactor that works in concert
with various transcription factors, it is highly likely that other biological processes
such as autophagy would be involved in the regulation of stem cell activation.
Despite its direct binding and activation of Pgc-1α promoter, Oct-4 might also wield
indirect transcriptional control over Pgc-1α expression given its pioneering activity
to shape chromatin conformation and epigenomic status of target sites (67). It can
be speculated that Oct-4 occupies distal enhancers for Pgc-1α and grants access
for the transcription factor and coactivator complex to regulate Pgc-1α gene
expression.
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The evidence for the perinatal transition of nMSCs to aMSCs has been
reported in a lineage tracing study in which committed osteogenic progenitors,
when labeled with Osterix perinatally, contribute not only to nascent bone tissues
but also to long-lived adult bone marrow stroma (15). Consistent with this, our
study finds that the proliferation and multilineage differentiation capacities of
nMSCs decline soon after birth (P7), implicating abrupt environmental changes
that nMSCs encounter during early postnatal development could drive the perinatal
stem cell transition. Tissue-resident somatic stem cells such as MSCs and
hematopoietic stem cells (HSCs) have been shown to rely on anaerobic glycolysis
as an adaptation to their hypoxic niche and for their lifelong maintenance (31-34).
Given that hypoxia-induced Hif-1α can induce anaerobic glycolysis while restricting
mitochondrial respiration in HSCs (68,69), it is plausible that nMSCs ousted from
the oxygen source and trapped in hypoxic regions of rapidly developing tissues
might rewire their metabolic programs from aerobic to anaerobic glycolysis and
become long-term self-renewing aMSCs.

Recently, a transgenic mouse study has reported the role of Pgc-1α in skeletal
stem cells in osteoporotic or aged mice (70). Yet little is known about the role of
Pgc-1α in developing skeletal tissues. Unlike the minimal effect of Pgc-1α deletion
on adult skeletal homeostasis (70), we report that Pgc-1α deficiency causes
perinatal lethality and depauperate skeletal phenotypes with overall undersized
and unmatured osseous tissues during perinatal development. Notably, these
developmental defects are observed in both craniofacial and appendicular
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skeletons, indicating our findings can be broadly applicable to different skeletal
tissues regardless of their embryonic origins and ossification types. Despite the
discernible phenotypes of Pgc-1α-null skeletons, our knockout model might not be
manifesting complete phenotypes due to the functional redundancy between Pgc1 homologues (i.e., Pgc-1β) (71,72) that might be compensating for the Pgc-1α
deficiency.

The close homolog of Pgc-1α, Pgc-1β also coordinates iron uptake in
mitochondrial biogenesis and controls osteoclast activation (73). Pgc-1β deletion
in monocyte lineage blocks osteoclastogenesis in vivo (74). However, the role of
Pgc-1α in osteoclastogenesis is still largely unknown. To reveal the biological roles
of Pgc-1α and Pgc-1β in skeletal homeostasis, conditional deletion of Pgc-1α and
Pgc-1β in either osteoblast lineage or osteoclast precursors will be critical to
understand the detailed molecular mechanisms. In addition to direct regulation on
bone metabolism, Pgc-1α reportedly serves as an important transcriptional coactivator to control expression of brown fat genes (75). As adipocytes are critical
to regulate bone homeostasis, Pgc-1α might be through bone-fat imbalance to
reduce osteogenesis in whole body genetic depletion models. It is well known that
the loss of Pgc-1α promotes inflammation by activating NF-kB signaling (76). As
NF-kB-mediated inflammation has often been linked to osteoporosis and oxidative
stress (77), osteoimmunology induced by the compound Pgc-1α depletion model
may also affect bone homeostasis.
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In summary, by studying stem cells in perinatal transition, the present study
illuminates a novel mechanism by which stem cells convert their metabolic and
functional states befitting life-stage-specific roles during craniofacial development
and homeostasis.

Limitations of Study
The global knockout model used in this study cannot rule out confounding
systemic effects that can influence the observed phenotypes, given the broad
impacts that Pgc-1α exerts on systemic energy homeostasis (39,78). In addition,
our model cannot appraise the relative contribution of Pgc-1α to embryonic or
perinatal development, without using an inducible system. For the spatiotemporal
control of Pgc-1α deletion, we will generate an inducible, tissue-specific conditional
knockout (CKO) model in which Pgc-1α gene is deleted exclusively in neural-crestderived cells by using the Wnt1-CreERT line (Wnt1-CreERT; Pgc-1α fl/fl) (79). This
novel CKO mice will enable us to study the role of Pgc-1α specific to craniofacial
tissues at different developmental stages.

Given the reported functional convergence of Pgc-1α and Pgc-1β (71,72),
Pgc-1 homologues might regulate overlapping targets to compensate for the loss
of the other in our single knockout model. To determine whether Pgc-1α and Pgc1β share roles that are cumulatively required for the metabolism and activities of
MSCs in developing craniofacial skeleton, we will generate conditional Pgc-1α
/Pgc-1β double knockout mice by deleting Pgc-1α in craniofacial skeletal tissues
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of Pgc-1β-null background (Wnt1-Cre; Pgc-1αfl/fl; Pgc-1β-/-). In addition to
homologues, alternative splicing and post-translational modifications produce
structurally distinct Pgc-1α variants with differential tissue distribution and
biological functions, adding another layer of complexity to study Pgc-1α.

Our respirometry analysis scheme focuses on glycolysis and mitochondrial
oxidation with glucose as a substrate. However, other metabolic pathways such as
fatty acid oxidation (FAO) or glutaminolysis could also be the part of the metabolic
switch controlling stem/progenitor cell fate conversion. Thus, possible involvement
of these metabolic pathways awaits further investigation. We assessed RNA or
protein expression levels of key metabolic enzymes as a proxy for cellular or tissue
metabolic states. This approach provides a meaningful but fragmentary snapshot
of cellular or tissue metabolism but has limitations as it does not reflect the
dynamics of metabolite fluxes. Metabolomics approaches such as liquid
chromatography-mass spectrometry (LC-MS) using sorted cell populations will
provide more relevant and integrative views of MSC’s metabolic states.

RNA-seq analysis provides the comprehensive transcriptomic profiles and
related biological processes in nMSCs and aMSCs. We further focus our analysis
on differentially expressed genes (DEGs) confined to three categories including
MSC markers, cell cycle, and mitochondrial metabolism with functional validation
of candidate genes. However, DEGs enriched in other pathways such as response
to oxidative stress or growth factor signals might have biological relevance to
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metabolic reprogramming during stem cell transition, thus, would be an interesting
area for further research. We observe inconsistency in DEG expression patterns
between samples within the MSC groups, which might be ascribable to the batch
effect associated with cell isolation, culture condition, and RNA sample processing.
In addition, we only performed three independent batch samples for each group,
which may also enlarge batch effects in our RNA-seq analysis. This batch effect
might also largely reduce statistical significance during target gene identification.
To avoid batch effects and improve statistical significance, we will increase sample
size for RNA-seq analysis.

Though our study provides evidence of direct transcriptional control of Pgc-1α
expression by Oct-4, Oct-4 might also exert indirect or broader roles in regulating
Pgc-1α expression and related metabolism. To delineate Oct-4 cistrome and
enhancer activities, we will perform chromatin immunoprecipitation with
sequencing (ChIP-seq) for Oct-4 and H3K27ac in the proximity of metabolic gene
loci in wildtype and Oct-4-depleted nMSCs and aMSCs. In parallel, chromatin
accessibility will be screened by the assay for transposase-accessible chromatin
with sequencing (ATAC-seq) and aligned to the ChIP-seq data to evaluate the
chromatin accessibility of Oct-4 binding sites. For Oct-4 knockdown, we used
siRNA at much higher concentration than that used in the previous studies to
achieve 50% silencing. Our data indicated that 50% silencing of Oct-4 was
sufficient to reduce nMSC proliferation, multipotent differentiation, OxPhos activity,
as well as Pgc-1α downregulation; however, it is still unknown the effects of 100%
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depletion of Oct-4 in nMSCs. Our preliminary data using higher siOct-4
concentration (over 200 µM) showed significantly increased cell apoptosis,
implying Oct-4 may be important to keep in a certain level to maintain MSC survival
and self-renewal. In the future, we will try higher siOct-4 concentration to further
confirm our preliminary findings. As shRNA-mediated gene silencing is a more
sustainable, higher potency and less off-target effect approach, in the follow-up
study, we will use shRNA for more stable silencing of Oct-4.

Future Directions
The outstanding plasticity of stem cells endows them with the ability to adapt
quickly to constantly changing environments throughout their lifetime by
transforming their metabolic status and function. Upon sensing environmental
challenges and following intrinsic genetic programs, stem cells rewire their
metabolic scheme congenial to functional demands in different physiological
contexts. Yet, the molecular switch controlling the metabolic reprograming remains
elusive. By studying stem cells in perinatal transition, the proposed research will
elucidate novel mechanisms by which stem cells alter their metabolic and
functional states to support the life-stage-specific roles during craniofacial
development and homeostasis. Successful completion of this proposal will provide
deeper insight into stem cell evolution processes, thereby making a valuable
contribution to the field. This project will be a platform to explore the genetic and
metabolic regulation of MSC evolution processes. Three directions/aims will be
focused in the future: 1) to identify whether glycolytic genes such as Glut1
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expression is transcriptionally controlled by Oct-4/Pgc-1α, 2) to identify distinct
transcriptomic signatures of nMSCs at a single cell level, and 3) to identify if cellular
microenvironment can provide a niche to regulate stem cell reprogramming
through metabolic reconfiguration.

The present study demonstrates the correlation between Pgc-1-driven
mitochondrial metabolism and stem cell activation. Surprisingly, we discovered an
unexpected positive correlation between glycolysis activity and Oct-4/Pgc-1α axis.
To identify whether glycolytic genes such as Glut1 expression is transcriptionally
controlled by Oct-4/Pgc-1α, (1) we will perform a Seahorse assay using an XFe96
analyzer with live cells to measure simultaneously glycolytic activities. The
glycolytic activity will be measured to compare between nMSCs and aMSCs, WT
and Pgc-1α-/- nMSCs, and siControl and siOct-4-treated nMSCs. (2) Metabolite
analysis of glucose metabolism intermediates, such as fructose 1,6-bisphosphate
and pyruvate will be performed by ELISA analysis. (3) Glut1 promoter/enhancer
regions will be identified and analyzed to predict Oct-4/Pgc-1α binding sites for
luciferase assays and ChIP analysis. Overall, these studies will show that key
regulators of glycolysis are mostly regulated at the level of transcription.

It is established that neural crest derived MSCs are remarkably
heterogeneous within craniofacial region. Recent studies have discovered a
diverse population of adult Wnt1+ MSCs that are equipped with specific molecular
signature and function. However, much less is known about neonatal MSC
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heterogeneity. To identify distinct transcriptomic signatures of nMSCs at single cell
level, we will perform single cell RNA-seq (scRNA-seq) and bioinformatics
analyses using mouse MSCs and human MSCs to uncover functional groups of
Wnt1+ neural crest derived cells and translate to human applications. We
hypothesize that Wnt1+ nMSCs have unique and functionally significant
transcriptomic profiles that can regulate stromal cell subtypes to promote stemness
with distinct metabolic status. Pseudotime analysis will be performed to arrange
the mesenchymal lineage cells in a pseudo-timeline defined by their differentiation
stage. Thorough transcriptome analysis of differential regulated genes (p<0.01)
from individual clusters, along with pseudotime trajectory, will identify new markers
for stromal progenitor subpopulations.

Our study focuses on cell intrinsic regulation of metabolic program during stem
cell transition. On the other hand, metabolic remodeling could represent an
adaptation of cells to environments such as substrate availability, oxygen tension,
growth factor signals, and matrix stiffness. To identify if cellular microenvironment
can provide a niche to regulate cell reprogramming through metabolic
reconfiguration, we will focus on extracellular biomechanical impact on MSC
metabolome and function in different stages of life. As our RNA-seq data showed
that extracellular matrix (ECM) organization pathways are enriched in nMSCs
compared to aMSCs, we hypothesize that ECM organization pathways are highly
activated in nMSCs to promote cell proliferation and multilineage differentiation.
YAP/TAZ signaling pathway has been shown to play a key role in regulating MSC
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differentiation by high stiffness. (1) We will perform qPCR analysis to examine
YAP/TAZ downstream targets such as CTGF and ANKRD1 expression. (2) As
YAP/TAZ translocates to the nucleus on high stiffness but becomes predominantly
cytoplasmic on softer substrates, we will perform immunofluorescence staining
using YAP/TAZ antibodies to identify the location of YAP/TAZ in nMSCs and
aMSCs. (3) As we observed different morphology between nMSCs and aMSCs
and ECM stiffness imposes different degree of cell spreading, we will examine
whether YAP/TAZ regulates cell spreading between nMSCs and aMSCs. We will
use siRNA or shRNA to silence YAP/TAZ in nMSCs and observe cell morphology,
cell spreading and YAP/TAZ location in MSCs. The capacities of MSC proliferation
and multilineage differentiation will be examined in siControl and siYAP/TAZtreated nMSCs. Taken together, this project will lay the foundation for a long-term
research project with potential clinical applications benefitting patients suffering
from craniofacial disorders.

Clinical Relevance
Interestingly, we find open mid-palatal sutures in Pgc-1⍺-null neonates,
indicating potential involvement of Pgc-1⍺ in the cleft palate pathogenesis where
the median and lateral palatine processes fail to fuse with each other to form the
palate. This finding encourages us to investigate if there’s a correlation between
Pgc-1⍺ mutation and craniofacial anomalies such as cleft lip and palate through
GWAS database search.

84

Conclusions
•

MSCs isolated from neonatal and adult craniofacial tissues represent a valid
model to study genetic and metabolic control of stem cell reprogramming
during craniofacial development and homeostasis.

•

nMSCs exhibit robust stem cell activity with higher proliferation and
multilineage differentiation potential than aMSC.

•

The Pgc-1α-OxPhos metabolic switch is required to support the robust
activity of nMSCs whereas the switch is turned off in aMSCs.

•

Pgc-1α deletion in nMSCs impairs the metabolic switch and stem cell
function,

resulting

in

perinatal

lethality,

growth

retardation,

and

developmental defects in craniofacial skeletal tissues.
•

Knockdown of Oct-4 in nMSCs by siRNA phenocopies the Pgc-1α-depleted
nMSCs by impairing OxPhos and stem cell activity.

•

Oct-4 regulates the Pgc-1α expression at the transcriptional level by directly
binding to the Pgc-1α promoter and inducing the promoter activity.

•

By studying stem cells in perinatal transition, this study defines the novel
Pgc-1α-OxPhos metabolic switch to improve stem-cell-based craniofacial
tissue regeneration.
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